GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MeiraGTx Holdings PLC (NAS:MGTX) » Definitions » Gross Profit

MeiraGTx Holdings (MeiraGTx Holdings) Gross Profit : $14.02 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is MeiraGTx Holdings Gross Profit?

MeiraGTx Holdings's gross profit for the three months ended in Dec. 2023 was $2.04 Mil. MeiraGTx Holdings's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $14.02 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. MeiraGTx Holdings's gross profit for the three months ended in Dec. 2023 was $2.04 Mil. MeiraGTx Holdings's Revenue for the three months ended in Dec. 2023 was $2.04 Mil. Therefore, MeiraGTx Holdings's Gross Margin % for the quarter that ended in Dec. 2023 was N/A%.

MeiraGTx Holdings had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


MeiraGTx Holdings Gross Profit Historical Data

The historical data trend for MeiraGTx Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MeiraGTx Holdings Gross Profit Chart

MeiraGTx Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial 13.29 15.56 37.70 15.92 14.02

MeiraGTx Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.29 3.33 3.54 5.10 2.04

Competitive Comparison of MeiraGTx Holdings's Gross Profit

For the Biotechnology subindustry, MeiraGTx Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MeiraGTx Holdings's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where MeiraGTx Holdings's Gross Profit falls into.



MeiraGTx Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

MeiraGTx Holdings's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=14.017 - 0
=14.02

MeiraGTx Holdings's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=2.04 - 0
=2.04

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.02 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

MeiraGTx Holdings's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=2.04 / 2.04
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


MeiraGTx Holdings  (NAS:MGTX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

MeiraGTx Holdings had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


MeiraGTx Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of MeiraGTx Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


MeiraGTx Holdings (MeiraGTx Holdings) Business Description

Traded in Other Exchanges
Address
450 East 29th Street, 14th Floor, New York, NY, USA, 10016
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Executives
Perceptive Life Sciences Master Fund Ltd director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Johnson & Johnson 10 percent owner ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
Robert K Zeldin officer: Chief Medical Officer C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Robert J Wollin officer: General Counsel and Secretary 450 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Debra Yu director C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Alexandria Forbes director, officer: President & CEO C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Richard Giroux officer: Chief Operating Officer C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Stuart Naylor director, officer: Chief Dev. Officer C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Joel S Marcus director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Thomas E Shenk director C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Nicole Seligman director C/O VIACOM INC., 1515 BROADWAY, NEW YORK NY 10036
Perceptive Advisors Llc director, 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ellen Hukkelhoven director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

MeiraGTx Holdings (MeiraGTx Holdings) Headlines

From GuruFocus

MeiraGTx to Participate in Upcoming Investor Conferences

By sperokesalga sperokesalga 04-20-2023

MeiraGTx to Participate in Upcoming Investor and Scientific Conferences

By GuruFocusNews GuruFocusNews 04-19-2022

MeiraGTx Announces $60 Million Private Placement of Ordinary Shares

By sperokesalga sperokesalga 05-03-2023